Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Oncoimmunology 2017;6(5):e1308618
Date
06/24/2017Pubmed ID
28638731Pubmed Central ID
PMC5468000DOI
10.1080/2162402X.2017.1308618Scopus ID
2-s2.0-85019019970 (requires institutional sign-in at Scopus site) 18 CitationsAbstract
Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies. Unfortunately, MM continues to cause significant morbidity and most patients eventually succumb to the disease. As in other areas of cancer, immunotherapy in MM has also evolved and holds promise to deliver long-lasting remissions or even cure. The signaling lymphocyte activation molecules (SLAM) family of surface proteins represents a group of potential targets for immunotherapy in MM as some of the family members are expressed consistently on plasma cells and also on myeloma propagating pre-plasma cells. Here, we review the SLAM family members in detail, describe their tissue distribution, biologic pathways, as well as relevant pre-clinical studies and clinical trials in MM. Our review demonstrates the value of SLAM family receptors as potential targets for anti-myeloma immunotherapies and outlines how immunotherapeutic approaches can be developed.
